These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15670184)

  • 1. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Schlumberger M
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):119-20. PubMed ID: 15670184
    [No Abstract]   [Full Text] [Related]  

  • 2. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
    Castagna MG; Brilli L; Pilli T; Montanaro A; Cipri C; Fioravanti C; Sestini F; Capezzone M; Pacini F
    J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
    Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
    Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a second recombinant human thyrotropin stimulation test useful? The value of postsurgical undetectable stimulated thyroglobulin level at the time of remnant ablation on clinical outcome.
    Prior-Sánchez I; Barrera Martín A; Moreno Ortega E; Vallejo Casas JA; Gálvez Moreno MÁ
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):97-107. PubMed ID: 27327536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum thyroglobulin in the diagnosis of metastases of differentiated thyroid cancer. Effect of suppressive thyroid hormone substitution on the diagnostic accuracy of thyroglobulin values].
    Müller-Gärtner HW; Schneider C; Tempel MT
    Nuklearmedizin; 1986 Oct; 25(5):194-200. PubMed ID: 3797259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
    Zöphel K; Wunderlich G; Smith BR
    Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of efficacy of various methods of thyroglobulin measurements in differentiated thyroid cancer].
    Czernik E; Deja R; Gubała E; Kukulska A; Turska M; Dabrowska-Czuba E; Bartnikowa W; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():339-48. PubMed ID: 12182046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.
    Smallridge RC; Meek SE; Morgan MA; Gates GS; Fox TP; Grebe S; Fatourechi V
    J Clin Endocrinol Metab; 2007 Jan; 92(1):82-7. PubMed ID: 17077133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin.
    Wartofsky L;
    Thyroid; 2002 Jul; 12(7):583-90. PubMed ID: 12193302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
    Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
    J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.